The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells

Cancer Biology and Therapy

Volumn 8, Issue 22, 2009, Pages 2185-2192

  Huang, Catherine ^a   Zhang, Xiang M ^a   Tavaluc, Raluca T ^a   Hart, Lori S ^a   Dicker, David T ^a   Wang, Wenge ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 fluorouracil; ALDH; Cancer stem cell; Cytotoxicity; Ellipticine; Flow cytometry; Mutant p53; p53; Side population

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ELLIPTICINE; ELLIPTICINE DERIVATIVE; FLUOROURACIL; HYBRID PROTEIN; NUCLEAR PROTEIN; PROTEIN P53; PYRIMIDINE DERIVATIVE; SYNTHETIC DNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CANCER STEM CELL; COLON TUMOR; DRUG EFFECT; DRUG POTENTIATION; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; REPORTER GENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; DRUG SYNERGISM; ELLIPTICINES; FLUOROURACIL; GENES, P53; GENES, REPORTER; GENES, SYNTHETIC; GENETIC VECTORS; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PYRIMIDINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84862740746     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.22.10446     Document Type: Article

References (22)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009; 137:413-31.
3. Bassett EA, Wang W, Rastinejad F, El-Deiry WS. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008; 14:6376-86.
4. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22:7486-95. (Pubitemid 37487171)
5. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008; 7:2034-8.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105-11.
7. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103:11003-8. (Pubitemid 44148408)
8. Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 2008; 7:2039-46.
9. Das S, El-Deiry WS, Somasundaram K. Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 2003; 22:8394-402. (Pubitemid 37523891)
10. Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet 1997; 17:141-3.
11. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1:47-55.
12. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302-13.
13. Jin Z, McDonald ER, 3rd, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004; 279:35829-39. (Pubitemid 39100590)
14. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507-11.
15. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59.
16. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Altaba AR. Hedgehog-gli signaling regulates human glioma growth, cancer stem cell self-renewal and tumorigenicity. Curr Biol 2007; 17:165-72. (Pubitemid 46107823)
17. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li Y-M, Eberhart CG. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-52. (Pubitemid 44289197)
18. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy- resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL receptor DR4. Cancer Biol Ther 2007; 6:1490-5. (Pubitemid 351590363)
19. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24:8541-55. (Pubitemid 39245075)
20. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12:66-80. (Pubitemid 47001783)
21. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-72. (Pubitemid 350138099)
22. Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007; 6:2554-62. (Pubitemid 350058675)